Investigational drug · Phase 3
rugonersen
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Angelman Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "rugonersen"
First trial start
2026
Jun 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rugonersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Angelman Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "rugonersen" as an intervention, largest first.
- BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.Pivotal-lookingRecruiting
OHB Pediatrics Ltd.Industry
NCT07605429 · 165 participants (planned) · Start Jun 23, 2026 · Primary completion Mar 2029
Drug: rugonersen · For: Angelman Syndrome
Sites: Los Angeles, California; San Diego, California; Aurora, Colorado · 10 sites in all
Oak Hill Bio LtdIndustry
NCT07136454
Drug: Rugonersen · For: Angelman Syndrome
Newest research
PubMed records naming it or its code names, newest first.
- Emerging disease-modifying therapies for Angelman syndrome: A comprehensive review for pediatric neurologists.
Samanta D · Brain Dev 2026
- The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial.
Hipp JF, Bacino CA, Bird LM, et al. · Nat Med 2025
- Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeys.
Jagasia R, Bon C, Rasmussen SV, et al. · Nucleic Acids Res 2025
Also in development for Angelman Syndrome
- obudanersenION582Phase 33 trials
Ionis Pharmaceuticals · Angelman Syndrome
- GTX-102Phase 21 trial
Ultragenyx Pharmaceutical Inc · Angelman Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.